Genmab — Marts 2016
-
Enig Budweis.
-
fra investtech. Genmab (GEN) gik svagt op på 856 kroner svarende til en stigning på 1.60 procent. Aktien brød op gennem modstanden ved 850 kroner i en omvendt-hoved-og-skuldre-formation. Dette udløste et købssignal , og en videre stigning til 1150 kroner i løbet af tre måneder indikeres
-
Hvad så med de markeder der er åbne idag ????
-
Mere positivt om patient, der får Daratumumab. Afsnit er fra artikel skrevet 21. marts 2016. Link er til hele artiklen.
-
For one of my patients, the approval of daratumumab (Darzalex), a human antibody aimed at a surface marker on the myeloma plasma cells named CD38, could not have come at a better time. He had exhausted most standard treatments, including experimental regimens on clinical trial. His bone marrow could not withstand any
assault from chemotherapy... -
...After much discussion, we agree to start daratumumab. He has had an excellent response, one of the 30 percent of patients who usually respond to this drug, including bone marrow recovery that may allow him to explore other options later on, a true success story. http://www.mywcms.org/news-and-events/newsroom/multiple-myeloma-new-drugs-offer-hope-to-patients
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind